Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SeluDex
ISRCTN92323261Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, open-label trial of selumetinib and dexamethasone in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Birmingham. Primary endpoints: Recommended Phase II dose selection and Treatment response. Started May 2018; status: completed.
02
Drugs
selumetinibdexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN92323261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92323261.